MHRA approved deuruxolitinib for severe alopecia areata in adults and explicitly said it would continue to keep the medicine’s safety and effectiveness under close review. Meanwhile, EMA listed new ESMP training for industry and published continued CVMP activity for March 2026.
These items come from different parts of the regulatory world, but together they show a common theme: regulator attention is becoming more continuous, more digital, and more publicly visible across multiple domains. That synthesis is an inference from the three official updates.
For global-watch readers, this is the kind of week that rewards scanning beyond one agency or one product class. A narrow watchlist can miss the broader direction of travel.
0 Comments